William Blair Reaffirms “Outperform” Rating for Axon Enterprise (NASDAQ:AXON)

William Blair restated their outperform rating on shares of Axon Enterprise (NASDAQ:AXON) in a report released on Wednesday morning, RTT News reports.

Other equities analysts have also recently issued reports about the stock. StockNews.com cut shares of Axon Enterprise from a buy rating to a hold rating in a research note on Thursday, March 14th. Argus assumed coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They set a buy rating and a $380.00 price target for the company. Morgan Stanley lifted their price target on shares of Axon Enterprise from $250.00 to $285.00 and gave the stock an equal weight rating in a research note on Wednesday, February 28th. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a buy rating in a research report on Wednesday, February 28th. Finally, Needham & Company LLC reissued a buy rating and issued a $400.00 price objective on shares of Axon Enterprise in a research report on Wednesday. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of Moderate Buy and a consensus price target of $314.91.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON opened at $308.23 on Wednesday. Axon Enterprise has a 52 week low of $175.37 and a 52 week high of $329.87. The stock has a market capitalization of $23.26 billion, a P/E ratio of 134.01 and a beta of 0.93. The firm has a fifty day simple moving average of $304.22 and a two-hundred day simple moving average of $261.92. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. On average, analysts expect that Axon Enterprise will post 2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Several large investors have recently modified their holdings of the business. Planned Solutions Inc. bought a new stake in shares of Axon Enterprise in the 1st quarter valued at about $366,000. UMB Bank n.a. raised its stake in shares of Axon Enterprise by 3,924.5% during the 1st quarter. UMB Bank n.a. now owns 17,869 shares of the biotechnology company’s stock worth $5,591,000 after acquiring an additional 17,425 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Axon Enterprise during the 1st quarter worth approximately $125,000. SYSTM Wealth Solutions LLC raised its stake in shares of Axon Enterprise by 2,359.5% during the 1st quarter. SYSTM Wealth Solutions LLC now owns 2,066 shares of the biotechnology company’s stock worth $646,000 after acquiring an additional 1,982 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new position in shares of Axon Enterprise during the 1st quarter worth approximately $442,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.